Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 6, 2009, Pages 507-516

  Blasi, Eileen ^a   Bamberger, Mark ^a   Knight, Delvin ^a   Engwall, Mike ^a   Wolk, Robert ^a   Winter, Steven ^a   Betts, Allison ^a   John Baptiste, Annette ^a   Keiser, Joan ^a  

^a PFIZER INC   (United States)

Author keywords

Atherosclerosis; Blood pressure; CETP inhibitor; Cholesterol; Hypertension

Indexed keywords

ALDOSTERONE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CP 529 414; CP 532 623; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TORCETRAPIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENOME; HUMAN; LOW DRUG DOSE; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; ALDOSTERONE; ANIMALS; ANTICHOLESTEREMIC AGENTS; BLOOD PRESSURE; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; MACACA FASCICULARIS; MALE; MIDDLE AGED; QUINOLINES; RENIN-ANGIOTENSIN SYSTEM; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 68249140219     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181a8184c     Document Type: Article

References (27)

1. Gordon DJ, Rifkind BM. High-density lipoprotein-the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
2. Barter PJ, BH Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:160-167.
3. Brewer HB Jr. Increasing HDL cholesterol levels. N Engl J Med. 2004; 350:1491-1494.
4. Sugano M, Makino N, Sawada S, et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem. 1998;273:5033-5036. (Pubitemid 28108660)
5. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406: 203-207. (Pubitemid 30469005)
6. Morehouse LA, Sugarman ED, Bourassa PA, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res. 2007;48:1263-1272.
7. de Haan W, de Vries-van der Weij J, van der Hoorn JW, et al. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation. 2008;117: 2515-2522.
8. Clark RW, Ruggeri RB, Cunningham D, et al. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res. 2006;47:537-552. (Pubitemid 43345595)
9. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-1515. (Pubitemid 38477775)
10. McKenney JM, Davidson MH, Shear CL, et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol. 2006;48:1782-1790. (Pubitemid 44648632)
11. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122. (Pubitemid 350146106)
12. Nissen SE, Tardif J-C, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356: 1304-1316. (Pubitemid 46513296)
13. Kastelein JJP, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620-1630. (Pubitemid 46631671)
14. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intimamedia thickness in mixed dyslipidemia (RADIANCE 2 study): a randomized, double-blind trial. Lancet. 2007;370:153-160.
15. DePasquale M, KD, Loging W, et al. Mechanistic Studies of Hemodynamics With a Series of Cholesteryl Ester Transfer Protein Inhibitors. Proceedings of the Late Breaking Science Session 12 American Heart Association Scientific Sessions. Dallas, TX; November 15, 2007.
16. Damon DB, Dugger RW, Hubbs SE, et al. Asymmetric synthesis of the cholesteryl ester transfer protein inhibitor torcetrapib. Org Process Res Dev. 2006;10:472-480. (Pubitemid 44012685)
17. Dalvie D, Chen W, Zhang C, et al. Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. Drug Metab Dispos. 2008;36:2185-2198.
18. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein. Arterioscler, Thromb Vasc Biol. 2004;24:490-497.
19. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-Induced Blood Pressure Elevation Is Independent of Cholesteryl Ester Transfer Protein Inhibition and Is Accompanied by an Increase in Circulating Aldosterone Levels. Proceedings of the Late Breaking Science Session 12 American Heart Association Scientific Sessions. Dallas, TX; November 19, 2007.
20. DePasquale M, Cadelina G, Knight DR, et al. Mechanistic studies of blood pressure in rats treated with a series of cholesteryl ester transfer protein inhibitors. Drug Dev Res. 2009;70:35-48.
21. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008;154: 1465-1473.
22. Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis. Insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 2008;118:2506-2514.
23. Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity. A pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation. 2008:CIRCULATIONAHA. 108.772665.
24. Betts A, Koup J, Winter S, et al. PK/PD Modeling of Torcetrapib Exposure/ Blood Pressure Response in Cynomolgous Monkeys and Translation to Humans. Proceedings of the PK/PD for Medicinal Chemists. Cambridge, MA; September 24, 2008.
25. de Grooth GJ, Kuivenhoven JA, Stalenhoef AFH, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 2002;105:2159-2165.
26. Davidson MH, McKenney JM, Shear CL, et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2006;48:1774-1781. (Pubitemid 44648633)
27. Hu X, Dietz JD, Xia C, et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein (CETP) inhibition. Endocrinology. 2009;150:2211-2219.